Saigopalakrishna S Yerneni
Overview
Explore the profile of Saigopalakrishna S Yerneni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carneiro G, Yerneni S, Chinaia K, Araujo A, Smith B, Eutsey R, et al.
Vaccine
. 2024 Dec;
44:126566.
PMID: 39617674
Diseases caused by Streptococcus pneumoniae (pneumococcus) produce a great impact on public health, killing about one million people annually despite available vaccines. Recent research has revealed that the pneumococcus produces...
2.
Werner Lass S, Smith B, Camphire S, Eutsey R, Prentice J, Yerneni S, et al.
mSphere
. 2024 Nov;
9(12):e0072724.
PMID: 39503503
Bacterial cells secrete extracellular vesicles (EVs), the function of which is a matter of intense investigation. Here, we show that the EVs secreted by the human pathogen (pneumococcus) are associated...
3.
Azambuja J, Yerneni S, Maurer L, Crentsil H, Debom G, Klei L, et al.
bioRxiv
. 2024 Oct;
PMID: 39386586
MALT1 protease is an intracellular signaling molecule that promotes tumor progression via cancer cell-intrinsic and cancer cell-extrinsic mechanisms. MALT1 has been mostly studied in lymphocytes, and little is known about...
4.
Chaudhary N, Kasiewicz L, Newby A, Arral M, Yerneni S, Melamed J, et al.
Nat Biomed Eng
. 2024 Oct;
8(11):1483-1498.
PMID: 39363106
Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicle for RNA therapeutics, partly because of established lipid structure-activity relationships focused on formulation potency. Yet such knowledge has not extended...
5.
Strelkova Petersen D, Weiss R, Hajj K, Yerneni S, Chaudhary N, Newby A, et al.
Adv Healthc Mater
. 2024 Jun;
13(22):e2400225.
PMID: 38888972
Lipid nanoparticles (LNPs) are proven safe and effective delivery systems on a global scale. However, their efficacy has been limited primarily to liver and immune cell targets. To extend the...
6.
Chaudhary N, Newby A, Arral M, Yerneni S, LoPresti S, Doerfler R, et al.
Proc Natl Acad Sci U S A
. 2024 Mar;
121(11):e2307810121.
PMID: 38437545
Treating pregnancy-related disorders is exceptionally challenging because the threat of maternal and/or fetal toxicity discourages the use of existing medications and hinders new drug development. One potential solution is the...
7.
Deng J, Ahmed S, Awoonor-Williams E, Banerjee P, Barecka M, Bickerton L, et al.
ACS Cent Sci
. 2024 Mar;
10(2):209-213.
PMID: 38435513
No abstract available.
8.
Werner Lass S, Camphire S, Smith B, Eutsey R, Prentice J, Yerneni S, et al.
bioRxiv
. 2024 Jan;
PMID: 38168155
Bacterial cells secrete extracellular vesicles (EVs), the function of which is a matter of intense investigation. Here, we show that the EVs secreted by the human pathogen (pneumococcus) are associated...
9.
Ludwig N, Yerneni S, Harasymczuk M, Szczepanski M, Gluszko A, Kukwa W, et al.
Br J Cancer
. 2023 Feb;
128(9):1733-1741.
PMID: 36810911
Objectives: Contributions of TGFβ to cancer progression are well documented. However, plasma TGFβ levels often do not correlate with clinicopathological data. We examine the role of TGFβ carried in exosomes...
10.
Melamed J, Yerneni S, Arral M, LoPresti S, Chaudhary N, Sehrawat A, et al.
Sci Adv
. 2023 Jan;
9(4):eade1444.
PMID: 36706177
Systemic messenger RNA (mRNA) delivery to organs outside the liver, spleen, and lungs remains challenging. To overcome this issue, we hypothesized that altering nanoparticle chemistry and administration routes may enable...